David McIntosh: Concrete Performance Targets for Rare Disease Patients
David McIntosh, Founder and Chair of United Plasma Action, shared PPTA Europe’s post on LinkedIn, adding:
“As yet another Rare Disease Day rolls round, it certainly behoves us all to pause and reflect upon the dire circumstances of the millions of patients and undiagnosed sufferers in this World currently suffering and dying from lack of appropriate care.
With upwards of 300 million people in this category, globally, they must surely be our key focus.
There can be no doubt that the commemoration of World Rare Disease Day, and the widespread publicity associated with it, will have beneficial effects.
To optimise these, however, consequent action will be required.
Awareness has potential value. Action will save lives.
A footnote here may be of value –
It will surely be helpful to approach February 28th with three numbers clearly in mind
- the number of unserved and underserved patients and undiagnosed sufferers, globally, in 2024/’25
- the number as it stands now
- the number the International Plasma Community is determined to see achieved by the end of 2026.
What those 300 million people our there need to know, please God, is that we’re making real solid progress towards relieving their suffering, and are determined to make even more progress – much more progress – in the years ahead.
Concrete performance targets will surely help towards that end ….”
PPTA Europe shared a post on LinkedIn:
“Rare diseases can be isolating and scary. The plasma community supports many patients experience rare diseases and is proud to raise awareness for Rare Disease Day occuring later this month (28 Feb).
Every year, thanks to better diagnostic tools and increased provider education, more patients are diagnosed with life-threatening plasma protein-related disorders, such as:
- Immune deficiencies
- Immune-mediated peripheral neuropathies
- Hereditary angioedema
- Alpha-1 antitrypsin deficiencies
- Haemophilia and other bleeding disorders
- And more
These aren’t your everyday health issues. They can be incredibly challenging to live with, and they often require lifelong treatment. In many cases, plasma-derived medicines are the only option to treat these rare diseases.
Many patients report not only improvements to their physical health after starting these unique therapies, but also share improvements in their mental health and overall happiness as well.
If you found this post insightful, please like and share.”

Find the latest updates on Hemostasis Today.
-
Oct 5, 2026, 15:31Irma Bagdoniene: Multidisciplinary Management of High-Risk Familial Hypercholesterolaemia and CAD
-
Oct 5, 2026, 15:00Serena Williams and Pulmonary Embolism: From Personal Crisis to Lessons in Venous Thromboembolism
-
Oct 5, 2026, 14:55Marco Moscarelli: 3D Reconstruction Enhances Volumetric Assessment of Post-TAVI Thrombosis
-
Oct 5, 2026, 13:24Abdul Muqtadir Abbasi: Diagnostic Pearls for Evaluating Isolated Thrombocytopenia in Residents
-
Oct 5, 2026, 13:16Katerina Pavenski: Rethinking What ‘Normal’ Means for Iron Deficiency
-
Oct 5, 2026, 13:09Rick Matthews: Balancing Established VTE Partnerships with Innovative Interventional Technologies
-
Oct 5, 2026, 13:01Nawsherwan Mohammad: Recognizing TTP Before the ADAMTS13 Result Arrives
-
Oct 5, 2026, 12:51Bruno Pougault: The Hidden Challenges Behind Anti Xa Testing
-
Oct 5, 2026, 12:41Syed Huzaifa Khan: Rethinking CTRP12 as a Biomarker for In Stent Restenosis